We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




The Tumor Suppressor Pannexin1 Modulates Intercellular Binding

By LabMedica International staff writers
Posted on 21 Feb 2012
A novel three-dimensional growth chamber was used to determine how the tumor-suppressive protein Pannexin 1 (Panx1) functions to maintain cellular aggregates and reduce the likelihood of cancer progression.

Investigators at Brown University (Providence, RI, USA) worked with cultures of rat C6 glioma cells. More...
These cells normally lack functioning Panx1. However, for this study, some C6 cells were genetically engineered to express Panx1.

The cells were cultured in novel three-dimensional growth chambers that provided them with a microenvironment that closely mimicked that found in vivo. Results published in the January 20, 2012, online edition of the Journal of Biological Chemistry revealed that after 24 hours in the growth chambers, cells with active Panx1 were able to form large multicellular tissues much faster and more tightly than the unaltered cancer cells.

Treatment with the drugs carbenoxolone (CBX) and probenecid (PBN), which directly and specifically block Panx1 channels respectively, confirmed that Panx1 was involved in accelerating aggregate assembly, and that exogenous ATP could reverse the inhibitive effects of CBX. These results indicated that Panx1 channels acted as conduits for ATP secretion that stimulated molecular pathways in the cell membrane linked to formation of stable intercellular bonds.

“In healthy tissues, the recently discovered protein Pannexin1 may be playing an important role in upholding the mechanical integrity of the tissue,” said first Brian Bao, doctoral student at Brown University. “When we develop cancer, we lose Pannexin1 and we lose this integrity. Using their single-cell systems, others have been able to carefully study individual pieces of this cascade. We came from a different perspective. Because the strength of our assay is that we can look at gross multicellular behavior in 3-D, we could ask, ‘Does this actually manifest into something tangible on the multicellular level?’

Related Links:

Brown University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.